250601-08-2

Upstream product

• 1026622-55-8 [(E)-4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzyloxyimino]-(4-phenoxy-phenyl)-acetic acid ethyl ester 
• 101-84-8 diphenylether 
• 62936-33-8 ethyl 2-oxo-2-(4-phenoxyphenyl)acetate 
• 103789-66-8 4-(5-methyl-2-phenyl-4-oxazolylmethoxy)-benzaldehyde 
• 250602-53-0 4-{[4-(chloromethyl)phenoxy]methyl}-5-methyl-2-phenyl-1,3-oxazole 
• 250602-52-9 {4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl}methanol 
• 250602-60-9 ethyl (E)-2-(hydroxyimino)-2-(4-phenoxyphenyl)acetate 
• 144-55-8 sodium hydrogencarbonate 
• 250602-61-0 ethyl (Z)-2-(hydroxyimino)-2-(4-phenoxyphenyl)acetate 

Relevant academic research and scientific papers

ABC EXPRESSION PROMOTERS

The ABCA1 mRNA expression-promoting agent, LXRα mRNA expression-promoting agent, ABCG1 mRNA expression-promoting agent, cholesterol efflux-promoting agent, cholesteryl ester accumulation-inhibiting agent, ACAT-1 mRNA expression-inhibiting agent and CEH mRNA expression-promoting agent of the present invention are excellent in the ability to control cholesterol distribution in the body and have low toxicity.

Neovascularization inhibitors

An angiogenesis inhibitor containing a compound represented by the formula wherein R4 is an optionally substituted hydrocarbon group and the like; Xa is a bond and the like; k is an integer of 1 to 3; Ya is an oxygen atom and the like; ring Ea is a benzene ring optionally having additional substituent(s); p is an integer of 1 to 8; R5 is a hydrogen atom and the like; q is an integer of 0 to 6; r is 0 or 1; R8 is a hydroxy group and the like; and R6 and R7 are hydrogen atoms and the like, or a salt thereof is useful as an agent for the prophylaxis or treatment of tumor and the like.

BODY WEIGHT GAIN INHIBITORS

An agent for inhibiting body weight gain derived from a PPARγ agonist-like substance, which contains a PPARδ agonist-like substance, is useful for the treatment of diabetes and the like.

Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives

A novel series of oxyiminoacetic acid derivatives were synthesized in an effort to develop a potent antidiabetic agent, which does not contain the 2,4-thiazolidinedione moiety. These compounds were evaluated for glucose and lipid lowering effects in genetically obese and diabetic KKAy mice. Several of the compounds showed strong antidiabetic activity, including functional potency at peroxisome proliferator-activated receptor (PPAR)-γ. (Z)-2-[4-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino]-2-(4- phenoxyphenyl)acetic acid (25) significantly reduced plasma glucose (33%, p0.01) and plasma triglycelide levels (43%, p0.01) even at a dosage of 0.001% in diet. Pharmacokinetic analyses of 25 are also reported.

Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.